Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

A rational approach to androgen therapy for hypogonadal men with prostate cancer

International Journal of Impotence Research volume 18, pages 26–31 (2006)Cite this article

Abstract

With earlier detection and improved survival from early stage prostate cancer, it is likely that the numbers of men presenting with hypogonadal symptoms following curative surgery for their cancer will increase. Although testosterone supplementation is effective in improving symptoms of hypogonadism, traditionally such therapy has been contraindicated in patients who have had prostate cancer. This paper reviews the evidence that testosterone therapy can be safely given to selected men with hypogonadism who have had prostate cancer but currently have no evidence of disease by clinical and prostate-specific antigen (PSA) criteria. Such patients should be treated cautiously and followed closely.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Oefelein M . Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998; 160: 1685–1688.

    Article  CAS  PubMed  Google Scholar 

  2. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol 1997; 47: 727–737.

    Article  CAS  Google Scholar 

  3. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I . Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab 1990; 70: 792–797.

    Article  CAS  PubMed  Google Scholar 

  4. Hajjar RR, Kaiser FE, Morley JE . Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793–3796.

    Article  CAS  PubMed  Google Scholar 

  5. Davidson JM, Camargo CA, Smith ER . Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979; 48: 955–958.

    Article  CAS  PubMed  Google Scholar 

  6. World Health Organization. Third International Consensus Consultation on Prostate Cancer. Paris, France, 2002.

  7. Kaufman JM, Graydon RJ . Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172: 920–922.

    Article  CAS  PubMed  Google Scholar 

  8. Slater S, Oliver RTD . Testosterone. Its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000; 17: 431–439.

    Article  CAS  PubMed  Google Scholar 

  9. Shaneyfelt T, Husein R, Bubley G, Mantzoios CS . Hormonal predictors of prostate cancer; a meta-analysis. J Clin Oncol 2000; 18: 847–853.

    Article  CAS  PubMed  Google Scholar 

  10. Eaton NE, Reeves GK, Appleby PN, Key TJ . Endogenous sex hormones and prostate cancer; a quantitative review of prospective studies. Br J Cancer 1999; 80: 930–934.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Parsons JK, Carter HB, Landis P, Wright EJ, Plotz EA, Metler EJ . Higher serum free testosterone is associated with an increased risk of prostate cancer: results from the Baltimore Longitudinal Study on Aging. Proceedings from the 99th annual meeting of the American Urological Association. J Urol 2004; 171: 116. Abstract #439.

    Article  Google Scholar 

  12. Massengill JC, Sun L, Moal JW, Wu H, McLeod DG, Amling C et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670–1675.

    Article  PubMed  Google Scholar 

  13. Isom-Batz G, Bianco FJ, Kattan MW, Mulhall JP, Lilja H, Eastham JA . Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173: 1935–1937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Schatzl G, Madersbacher S, Hotel A, Gsur A, Pryer M, Hadinger G et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312–1315.

    Article  CAS  PubMed  Google Scholar 

  15. Morgantaler A, Bunning III CO, DeWolf WC . Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904–1906.

    Article  Google Scholar 

  16. Jackson JA, Waxman J, Spiekerman AM . Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989; 149: 2365–2366.

    Article  CAS  PubMed  Google Scholar 

  17. Loughlin KP, Richie JP . Prostate cancer after exogenous testosterone therapy for impotence. J Urol 1997; 157: 1845.

    Article  CAS  PubMed  Google Scholar 

  18. Curran MJ, Bihrle III W . Dramatic rise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53: 423–424.

    Article  CAS  PubMed  Google Scholar 

  19. Gaylis FD, Lin DW, Ignatoff JM, Amling CF, Tutrone RF, Cosgrove DJ . Prostate cancer in men using testosterone supplementation. J Urol 2005; 174: 534–538.

    Article  CAS  PubMed  Google Scholar 

  20. Gerstenbluth RE, Maniam PN, Corty EW, Seflel AD . Prostate specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23: 922–926.

    PubMed  Google Scholar 

  21. Wang C, Cunningham G, Dobs A, Ironmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel (Androgel), treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrin Metab 2004; 89: 2085–2098.

    Article  CAS  Google Scholar 

  22. Morales A, Lunenfeld B . Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male 2002; 5: 74–86.

    Article  CAS  PubMed  Google Scholar 

  23. Fowler Jr JE, Whitmore WF . Considerations for the use of testosterone with systemic chemotherapy in prostate cancer. Cancer 1982; 49: 1373–1377.

    Article  PubMed  Google Scholar 

  24. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC . Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517–523.

    Article  PubMed  Google Scholar 

  25. Antenor JV, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ . Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease. Urology 2005; 66: 156–160.

    Article  PubMed  Google Scholar 

  26. Twiss C, Slova D, Lepor H . Outcomes for Men Younger than 50 Years undergoing Radical Prostatectomy. Urology 2005; 66: 141–146.

    Article  PubMed  Google Scholar 

  27. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A . Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 2005; 173: 1455–1482.

    Article  Google Scholar 

  28. Kuban DA, Thames HD, Shipley WU . Defining recurrence after radiation for prostate cancer. J Urol 2005; 173: 1871–1878.

    Article  PubMed  Google Scholar 

  29. Sandler HM . Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy. J Urol 2004; 172: S38–S41.

    Article  CAS  PubMed  Google Scholar 

  30. D'Amico AV, Manola J, Loffredo M, Renshaw AA, Dellacroce A, Kantoff PW . Six-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer. JAMA 2004; 292: 821–827.

    Article  CAS  PubMed  Google Scholar 

  31. Morales A . Androgen replacement therapy and prostate safety. Eur Urol 2002; 41: 113–120.

    Article  CAS  PubMed  Google Scholar 

  32. Agarwal PK, Oefelein MG . Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533–536.

    Article  CAS  PubMed  Google Scholar 

  33. Rhoden EL, Morgantaler A . Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of one year of treatment in men with prostatic intraepithelial neoplasm. J Urol 2003; 170: 2348–2351.

    Article  CAS  PubMed  Google Scholar 

  34. DeWeese TL . Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: the new standard? JAMA 2004; 292: 864–866.

    Article  CAS  PubMed  Google Scholar 

  35. Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC . A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000; 164: 1891–1894.

    Article  CAS  PubMed  Google Scholar 

  36. Gulley JL, Figg WD, Steinberg SM, Carter J, Hussain MH, Dahut WL . A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005; 173: 1567–1571.

    Article  CAS  PubMed  Google Scholar 

  37. Brawer MK . Testosterone replacement therapy for a man with prostate cancer. Rev Urol 2004; 6 (Suppl 6): S35–37.

    PubMed  PubMed Central  Google Scholar 

  38. Rhoden EL, Morgentaler A . Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Research Options, Aurora Urology, Aurora, CO, USA

    J Kaufman

Authors
  1. J Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Kaufman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaufman, J. A rational approach to androgen therapy for hypogonadal men with prostate cancer. Int J Impot Res 18, 26–31 (2006). https://doi.org/10.1038/sj.ijir.3901401

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901401

Keywords

This article is cited by

Search

Advanced search

Quick links